A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

An anonymous coder, writing to 404media under the fake name Aaron B, has also been feeling the malaise, and he's doing ...

Non-resident property transactions in India face compliance challenges, including obtaining TAN, depositing TDS, and filing e ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Until this year, the Guinness World Record was held by a nearly 13,000-square-foot ice labyrinth in New York that took the ...

The casual-dining chain’s 31% same-store sales number was shocking by any standard, and stands up to some of the best ...

All Points North explores why foreign nationals may face job discrimination in Finland and looks at measures to improve ...

Learn how to create a dynamic reports in Excel using one formula. Simplify calculations and automate your workflow ...